Palbociclib- Pfizer

Drug Profile

Palbociclib- Pfizer

Alternative Names: Ibrance; Iburance; Parvociclib; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onyx Pharmaceuticals; Pfizer
  • Developer Assistance Publique Hopitaux de Paris; Bergonie Institute; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; Georgetown University; German Breast Group; GlaxoSmithKline; iOMEDICO AG; Karolinska Institute; Merck & Co; National Cancer Institute (USA); Netherlands Cancer Institute; Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Brain metastases; Colorectal cancer; Gastrointestinal stromal tumours; Head and neck cancer; Prostate cancer; Urogenital cancer
  • Phase I/II Cancer; Malignant melanoma
  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Pancreatic cancer; Solid tumours
  • No development reported Glioblastoma; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mantle-cell-lymphoma(Combination therapy, Second-line therapy or greater) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top